Stock listing

OTC:CYDY CytoDyn Inc. Stock

Follow CytoDyn Inc. into a list and get an email when it puts out news.

Share price · OTC:CYDY

$0.222 USD -0.003 (-1.3%)

Close on Nov 20, 2026

Past year -26.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.221 – $0.237 USDNov 20, 2026
Volume
796,019 sharesNov 20, 2026
Market cap
$326.4M USDAt the close on Nov 20, 2026 · price × 1.47B shares outstanding
52-week range
$0.180 – $0.400 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$362,336 USDMedian day 1.17M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
CytoDyn Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:CYDY · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.222-0.003-1.3%$0.230$0.237$0.221796,019
$0.225-0.024-9.8%$0.250$0.255$0.2252,831,055
$0.250-0.001-0.3%$0.259$0.259$0.2421,174,321
$0.250+0.000+0.1%$0.250$0.265$0.2461,012,918
$0.250+0.015+6.2%$0.241$0.253$0.240976,731
$0.235+0.004+1.5%$0.235$0.250$0.232862,483
$0.232-0.001-0.5%$0.240$0.245$0.226564,529
$0.233-0.007-2.9%$0.232$0.240$0.230673,552
$0.240+0.010+4.4%$0.230$0.240$0.227541,175
$0.230+0.004+1.8%$0.238$0.240$0.225655,946
$0.226-0.003-1.2%$0.222$0.230$0.220510,083
$0.229+0.002+1.0%$0.225$0.229$0.220240,706
$0.226+0.006+2.8%$0.221$0.235$0.221709,237
$0.220+0.0000.0%$0.243$0.243$0.220284,148
$0.220-0.005-2.2%$0.225$0.230$0.217386,293
$0.225+0.013+6.1%$0.217$0.228$0.212463,617
$0.212-0.006-2.6%$0.220$0.225$0.2121,303,483
$0.218-0.018-7.8%$0.237$0.240$0.2152,132,595
$0.236-0.024-9.2%$0.257$0.282$0.2362,753,371
$0.260+0.020+8.3%$0.240$0.277$0.2352,141,127
$0.240-0.010-4.0%$0.250$0.250$0.2402,401,300
$0.2500.0000.0%$0.250$0.260$0.2402,489,000
$0.2500.0000.0%$0.270$0.290$0.2407,348,600
$0.250+0.020+8.7%$0.230$0.290$0.2306,377,900
$0.230+0.020+9.5%$0.210$0.230$0.2103,962,300
$0.210+0.010+5.0%$0.200$0.210$0.2003,277,400
$0.2000.0000.0%$0.200$0.210$0.200991,600
$0.2000.0000.0%$0.200$0.210$0.200627,000
$0.2000.0000.0%$0.200$0.210$0.2001,172,200
$0.2000.0000.0%$0.200$0.200$0.2001,981,900
$0.2000.0000.0%$0.200$0.200$0.2001,778,000
$0.2000.0000.0%$0.200$0.200$0.2001,620,000
$0.2000.0000.0%$0.200$0.200$0.200620,600
$0.2000.0000.0%$0.200$0.210$0.200818,100
$0.2000.0000.0%$0.190$0.210$0.1901,527,700
$0.200-0.010-4.8%$0.210$0.210$0.2002,044,400
$0.210+0.010+5.0%$0.210$0.210$0.200643,700
$0.200-0.020-9.1%$0.210$0.230$0.2005,316,600
$0.220-0.010-4.3%$0.220$0.220$0.2101,994,300
$0.230+0.020+9.5%$0.220$0.230$0.2101,072,200
$0.2100.0000.0%$0.210$0.220$0.210684,000
$0.2100.0000.0%$0.210$0.210$0.200542,300
$0.210-0.010-4.5%$0.210$0.220$0.200723,600
$0.220+0.010+4.8%$0.220$0.220$0.2101,125,500
$0.2100.0000.0%$0.210$0.210$0.200900,100
$0.210+0.010+5.0%$0.210$0.210$0.2003,226,500
$0.2000.0000.0%$0.200$0.210$0.2001,213,700
$0.2000.0000.0%$0.220$0.220$0.200705,300
$0.2000.0000.0%$0.200$0.210$0.1901,476,400
$0.200+0.010+5.3%$0.190$0.200$0.1901,600,900
$0.190-0.010-5.0%$0.200$0.200$0.1802,408,600
$0.2000.0000.0%$0.190$0.210$0.1901,425,700
$0.2000.0000.0%$0.200$0.210$0.1902,076,900
$0.200-0.010-4.8%$0.210$0.210$0.2002,759,500
$0.2100.0000.0%$0.210$0.210$0.200872,900
$0.210-0.010-4.5%$0.230$0.230$0.2002,069,800
$0.220-0.020-8.3%$0.220$0.240$0.2102,691,200
$0.240+0.010+4.3%$0.230$0.240$0.220816,500
$0.2300.0000.0%$0.220$0.240$0.220938,000
$0.230-0.020-8.0%$0.250$0.260$0.2201,490,400
$0.250+0.013+5.5%$0.250$0.260$0.2301,709,800
$0.237+0.020+9.3%$0.220$0.249$0.2172,419,692
$0.217+0.007+3.2%$0.205$0.234$0.2001,320,223
$0.2100.0000.0%$0.210$0.210$0.200803,700
$0.210+0.010+5.0%$0.200$0.210$0.2001,155,000
Ticker
OTC:CYDY
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

What changed lately

Latest news

All CytoDyn Inc. news

CytoDyn Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
7 in the last 12 months · 7 in all · newest Nov 17, 2026 · oldest 2026
Decks
13 decks · latest Oct 19, 2026

Valuation

Statements: 4 quarters to Aug 31, 2026 · price Nov 20, 2026

Enterprise value
$345.8M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
0.44

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
CytoDyn Inc. · OTC:CYDYUS$326.4MUS$345.8Mn/an/an/an/an/an/a0.44
Lyell Immunopharma, Inc. · NASDAQ:LYELUS$339.3MUS$196.5Mn/a13,099×n/a1.8×n/a0.2×1.51
Avacta Group PLC · LSE:AVCTUS$337.8MUS$337.2Mn/a2,281×n/a68.5×n/a5.3×n/a
Inovio Pharmaceuticals, Inc. · NASDAQ:INOUS$329.7MUS$7.56Bn/a25,303×3.4×n/an/an/a0.70
Larimar Therapeutics, Inc. · NASDAQ:LRMRUS$328.6MUS$204.7Mn/an/an/a3.2×n/a0.1×1.48
C4 Therapeutics, Inc. · NASDAQ:CCCCUS$325.7MUS$175.5Mn/a5.4×n/a1.4×−282.2%0.2×1.46
Laekna, Inc. · HKEX:2105US$322.8MUS$154.7Mn/a9.7×n/a1.8×−214.9%0.0×n/a
Foresee Pharmaceuticals Co., Ltd. · TPEX:6576US$319.8MUS$303.4M469×21.2×n/a8.3×4.8%0.3×n/a
GI Innovation, Inc. · KRX:358570US$317.8MUS$288.6Mn/an/an/a4.4×n/a0.0×n/a
Atea Pharmaceuticals, Inc. · NASDAQ:AVIRUS$317.6MUS$126.6Mn/an/an/a1.8×n/a0.0×0.86
MapLight Therapeutics, Inc. · NASDAQ:MPLTUS$313.9MUS$29.84Mn/an/an/a0.7×n/a0.0×1.28
Median of the othersUS$324.2MUS$200.6M469×1,151×3.4×1.8×−214.9%0.1×1.37

Team and board

Officers

OfficerRole
Robert E. HoffmanChief Executive Officer
Lauren WilcoxenChief Operating Officer and Head of Regulatory Affairs
Tyler BlokChief Legal Officer
Jacob LalezariHead of Research and Translation Sciences

Board

DirectorRole
Tanya Durkee UrbachChair
Karen J. BrunkeDirector
Lishomwa C. NdhlovuDirector
Ryan DunlapDirector
Stephen M. SimesDirector

Events

QuarterResultsShare move
Q1 2027Oct 28, 2026+3.4%
Q4 2026Jul 29, 2026−5.0%
Q3 2026Apr 29, 20260.0%
Q2 2026Jan 28, 20260.0%
Q1 2026Sep 2, 2025 · After close−3.1%
Q4 2025Jul 30, 2025+11.1%
Q3 2025Apr 14, 2025 · After close+5.0%
Q2 2025Jan 14, 2025 · After close0.0%
Q1 2025Oct 15, 2024 · After close0.0%
Q4 2024Aug 15, 2024 · After close0.0%
All 20 quarters
QuarterResultsShare move
Q3 2024Apr 15, 2024 · After close+7.1%
Q2 2024Jan 16, 2024 · After close−5.0%
Q1 2024Oct 23, 2023 · After close−5.9%
Q4 2023Aug 30, 2023 · After close0.0%
Q3 2023Apr 10, 2023 · After close−6.1%
Q2 2023Jan 9, 2023 · After close0.0%
Q1 2023Oct 11, 2022 · After close+9.8%
Q4 2022Aug 15, 2022 · After close−4.8%
Q3 2022Apr 11, 2022 · After close−3.6%
Q2 2022Jan 10, 2022 · After close−20.0%

Open Events

Decks

DeckKindSlidesDate
Corporate Update (October 2026)Corporate update35 slidesOct 19, 2026
Investor Presentation (April 2026)Investor deck24 slidesApr 30, 2026
Technical Presentation (December 2022)Technical100 slidesDec 7, 2022
Shareholder Meeting (November 2021)Shareholder meeting22 slidesNov 24, 2021
Proxy Contest (October 2021)Proxy contest13 slidesOct 4, 2021
Investor Presentation (July 2021)Investor deck23 slidesJul 22, 2021
Investor Presentation (June 2021)Investor deck19 slidesJun 21, 2021
Shareholder Meeting (September 2020)Shareholder meeting22 slidesSep 30, 2020
Biotech Showcase January 2019Conference20 slidesMay 2, 2019
Investor Presentation (January 2019)Investor deck23 slidesJan 10, 2019
All 13 decks
DeckKindSlidesDate
Shareholder Meeting (November 2018)Shareholder meeting26 slidesNov 9, 2018
Investor Presentation (March 2018)Investor deck19 slidesMar 26, 2018
Investor Presentation (March 2017)Investor deck21 slidesMar 30, 2017

Open Decks

Financings

RaiseDate
Private placement of common shares
Closed: US$5M raised · US$0.24 a share
Use of proceeds: Develop the colorectal cancer program and explore leronlimab in earlier treatment lines and other cancers incl. TNBC, pancreatic cancer, glioblastoma
Nov 12, 2026

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue0266.0K0
Cost of revenue53.0K
Gross profit213.0K
Research and development7.24M2.63M27.0M53.4M52.6M42.5M38.2M20.2M
Operating income-38.6M9.66M-18.1M-40.6M-145.4M-104.6M-74.6M-55.9M-45.9M-27.3M
Depreciation and amortization17.0K18.0K29.0K175.0K781.0K1.80M2.03M1.25M356.1K366.4K
EBITDA-38.6M9.68M-18.0M-40.4M-144.6M-102.8M-72.6M-54.6M-45.6M-27.0M
Interest expense18.2M3.31M5.92M612.8K
Income before tax-42.7M3.75M-49.8M-79.8M-210.8M-176.5M-139.9M-63.5M-50.1M-25.8M
Income tax0000000-2.83M00
Net income-42.7M3.75M-49.8M-79.8M-210.8M-176.5M-139.9M-60.7M-50.1M-25.8M
Earnings per share, basic-0.030.00-0.05-0.10-0.31-0.30-0.33-0.23-0.23-0.17
Earnings per share, diluted-0.030.00-0.05-0.10-0.31-0.30-0.33-0.23

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents11.9M11.9M3.11M2.54M4.23M33.9M14.3M2.61M1.23M1.78M
Inventory0093.5M19.1M
Current assets13.9M17.9M10.8M10.8M10.5M36.1M36.8M5.37M3.32M6.12M
Property, plant and equipment73.0K134.0K55.0K29.3K11.2K17.3K
Total assets14.0M18.0M11.1M11.3M29.2M132.1M50.5M20.9M4.90M8.06M
Accounts payable13.2M14.7M29.6M62.7M68.0M65.9M29.5M16.2M15.8M4.28M
Current liabilities53.7M70.5M84.2M119.8M123.2M152.5M44.5M26.9M16.7M6.14M
Total debt38.3M45.4M45.0M45.7M42.2M42.2M0
Total liabilities123.7M114.1M127.9M120.8M123.6M153.1M53.0M29.8M18.1M9.16M
Shareholders' equity-109.7M-96.0M-116.8M-109.5M-94.4M-21.0M-2.48M-8.91M-13.2M-1.10M
Shares outstanding1.37B1.25B1.06B918.6M719.6M625.7M519.0M329.4M216.7M149.5M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-17.3M-8.77M-11.0M-25.1M-77.7M-117.6M-68.8M-50.5M-29.9M-26.7M
Capital spending-122.0K-41.0K-26.0K0-11.1K
Free cash flow-117.7M-68.8M-50.5M-29.9M-26.7M
Cash from investing00-122.0K-41.0K-45.0K0-11.1K
Cash from financing17.2M10.9M11.7M29.9M48.0M137.3M79.7M52.7M29.4M18.9M
Change in cash-51.0K2.09M766.0K4.82M-29.7M19.7M10.8M2.24M-544.1K-7.87M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 20, 2026Meeting outcomeSEC
8-K · Current reportNov 17, 2026Management or board changeSEC
4 · Change in ownershipOct 20, 2026Insider tradeSEC
DEFA14A · Additional proxy materialOct 19, 2026Meeting noticeSEC
8-K · Current reportOct 19, 2026Management or board changeSEC
10-Q · Quarterly reportOct 14, 2026Quarterly reportSEC
EFFECT · Notice that a registration is effectiveOct 8, 2026Other filingsSEC
424B3 · ProspectusOct 7, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 5, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveOct 5, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
DEF 14A · Proxy statementSep 28, 2026Meeting noticeSEC
S-3 · Registration statementSep 25, 2026Offer documentSEC
POS AM · Amendment to an effective registrationSep 25, 2026Offer documentSEC
POS AM · Amendment to an effective registrationSep 25, 2026Offer documentSEC
10-K · Annual reportAug 31, 2026Annual reportSEC
EFFECT · Notice that a registration is effectiveMay 21, 2026Other filingsSEC
424B3 · ProspectusMay 20, 2026Offer documentSEC
DMay 8, 2026Other filingsSEC
8-K · Current reportApr 30, 2026Current reportSEC
S-1 · Registration statementApr 22, 2026Offer documentSEC
424B3 · ProspectusApr 8, 2026Offer documentSEC
10-Q · Quarterly reportApr 8, 2026Quarterly reportSEC
424B3 · ProspectusMar 25, 2026Offer documentSEC
4 · Change in ownershipMar 24, 2026Insider tradeSEC
4 · Change in ownershipMar 24, 2026Insider tradeSEC
4 · Change in ownershipMar 24, 2026Insider tradeSEC
4 · Change in ownershipMar 24, 2026Insider tradeSEC
4 · Change in ownershipMar 24, 2026Insider tradeSEC
4 · Change in ownershipMar 24, 2026Insider tradeSEC
4 · Change in ownershipMar 24, 2026Insider tradeSEC
4 · Change in ownershipMar 24, 2026Insider tradeSEC
8-K · Current reportMar 24, 2026Material contractSEC
424B3 · ProspectusMar 9, 2026Offer documentSEC
8-K · Current reportMar 5, 2026FinancingSEC
424B3 · ProspectusJan 9, 2026Offer documentSEC
10-Q · Quarterly reportJan 9, 2026Quarterly reportSEC
424B3 · ProspectusDec 22, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 17, 2025Other filingsSEC
POS AM · Amendment to an effective registrationDec 10, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 3, 2025Other filingsSEC
424B3 · ProspectusDec 2, 2025Offer documentSEC
8-K · Current reportDec 1, 2025Current reportSEC
CORRESP · Letter to the SECNov 26, 2025Other filingsSEC
8-K · Current reportNov 21, 2025Meeting outcomeSEC
S-3 · Registration statementNov 4, 2025Offer documentSEC
DEFA14A · Additional proxy materialNov 3, 2025Meeting noticeSEC
8-K · Current reportNov 3, 2025Material contractSEC
10-Q · Quarterly reportOct 10, 2025Quarterly reportSEC
DEFA14A · Additional proxy materialSep 30, 2025Meeting noticeSEC
424B3 · ProspectusSep 29, 2025Offer documentSEC
DEF 14A · Proxy statementSep 29, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementSep 19, 2025Meeting noticeSEC
EFFECT · Notice that a registration is effectiveAug 22, 2025Other filingsSEC
CORRESP · Letter to the SECAug 19, 2025Other filingsSEC
CORRESP · Letter to the SECAug 18, 2025Other filingsSEC
UPLOAD · Letter from the SECJul 31, 2025Other filingsSEC
S-3 · Registration statementJul 25, 2025Offer documentSEC
10-K · Annual reportJul 25, 2025Annual reportSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 22, 2025Insider tradeSEC
424B3 · ProspectusMay 16, 2025Offer documentSEC
8-K · Current reportMay 16, 2025Current reportSEC
424B3 · ProspectusMay 6, 2025Offer documentSEC
8-K · Current reportMay 6, 2025Management or board changeSEC
424B3 · ProspectusApr 15, 2025Offer documentSEC
10-Q · Quarterly reportApr 14, 2025Quarterly reportSEC
424B3 · ProspectusJan 14, 2025Offer documentSEC
10-Q · Quarterly reportJan 14, 2025Quarterly reportSEC
8-K · Current reportNov 22, 2024Meeting outcomeSEC
4 · Change in ownershipOct 30, 2024Insider tradeSEC
4 · Change in ownershipOct 30, 2024Insider tradeSEC
4 · Change in ownershipOct 30, 2024Insider tradeSEC
4 · Change in ownershipOct 30, 2024Insider tradeSEC
4 · Change in ownershipOct 30, 2024Insider tradeSEC
4 · Change in ownershipOct 30, 2024Insider tradeSEC
4 · Change in ownershipOct 30, 2024Insider tradeSEC
424B3 · ProspectusOct 17, 2024Offer documentSEC
10-Q · Quarterly reportOct 15, 2024Quarterly reportSEC
DEF 14A · Proxy statementOct 11, 2024Meeting noticeSEC
EFFECT · Notice that a registration is effectiveOct 2, 2024Other filingsSEC
424B3 · ProspectusOct 1, 2024Offer documentSEC
10-K/A · Annual report, amendedSep 30, 2024Annual reportSEC
CORRESP · Letter to the SECSep 26, 2024Other filingsSEC
UPLOAD · Letter from the SECSep 17, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveSep 13, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveSep 13, 2024Other filingsSEC
POS AM · Amendment to an effective registrationSep 6, 2024Offer documentSEC
POS AM · Amendment to an effective registrationSep 6, 2024Offer documentSEC
S-1 · Registration statementSep 6, 2024Offer documentSEC
10-K · Annual reportAug 15, 2024Annual reportSEC
SC TO-I/AJul 22, 2024Acquisition or disposalSEC
424B3 · ProspectusJul 9, 2024Offer documentSEC
424B3 · ProspectusJul 9, 2024Offer documentSEC
SC TO-I/AJul 9, 2024Acquisition or disposalSEC
8-K · Current reportJul 9, 2024Current reportSEC
CORRESP · Letter to the SECJun 28, 2024Other filingsSEC
SC TO-I/AJun 28, 2024Acquisition or disposalSEC
8-K · Current reportJun 28, 2024Current reportSEC
CORRESP · Letter to the SECJun 20, 2024Other filingsSEC
SC TO-I/AJun 20, 2024Acquisition or disposalSEC
CORRESP · Letter to the SECJun 12, 2024Other filingsSEC
UPLOAD · Letter from the SECJun 10, 2024Other filingsSEC
8-K · Current reportJun 3, 2024FinancingSEC
SC TO-IJun 3, 2024Acquisition or disposalSEC
424B3 · ProspectusMay 6, 2024Offer documentSEC
424B3 · ProspectusMay 6, 2024Offer documentSEC
8-K · Current reportMay 6, 2024Current reportSEC
424B3 · ProspectusApr 16, 2024Offer documentSEC
424B3 · ProspectusApr 16, 2024Offer documentSEC
10-Q · Quarterly reportApr 15, 2024Quarterly reportSEC
424B3 · ProspectusApr 8, 2024Offer documentSEC
424B3 · ProspectusApr 8, 2024Offer documentSEC
8-K · Current reportApr 8, 2024Current reportSEC
8-K · Current reportMar 28, 2024FinancingSEC
4 · Change in ownershipMar 8, 2024Insider tradeSEC
424B3 · ProspectusMar 1, 2024Offer documentSEC
424B3 · ProspectusMar 1, 2024Offer documentSEC
424B3 · ProspectusFeb 22, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveFeb 22, 2024Other filingsSEC
3 · Initial statement of ownershipFeb 15, 2024Insider tradeSEC
CORRESP · Letter to the SECFeb 15, 2024Other filingsSEC
UPLOAD · Letter from the SECFeb 13, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedFeb 12, 2024Big-stake noticeSEC
S-1 · Registration statementFeb 6, 2024Offer documentSEC
424B3 · ProspectusJan 29, 2024Offer documentSEC
8-K · Current reportJan 29, 2024Management or board changeSEC
424B3 · ProspectusJan 19, 2024Offer documentSEC
10-Q · Quarterly reportJan 16, 2024Quarterly reportSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
8-K · Current reportDec 22, 2023Current reportSEC
424B3 · ProspectusDec 15, 2023Offer documentSEC
8-K · Current reportDec 14, 2023Current reportSEC
3 · Initial statement of ownershipNov 29, 2023Insider tradeSEC
424B3 · ProspectusNov 28, 2023Offer documentSEC
8-K · Current reportNov 28, 2023Current reportSEC
424B3 · ProspectusNov 22, 2023Offer documentSEC
8-K · Current reportNov 21, 2023Management or board changeSEC
424B3 · ProspectusNov 13, 2023Offer documentSEC
8-K · Current reportNov 9, 2023Meeting outcomeSEC
8-K · Current reportNov 3, 2023Current reportSEC
DEFA14A · Additional proxy materialNov 3, 2023Meeting noticeSEC
SC 13G · Big-stake noticeOct 25, 2023Big-stake noticeSEC
424B3 · ProspectusOct 24, 2023Offer documentSEC
10-Q · Quarterly reportOct 23, 2023Quarterly reportSEC
NT 10-Q · Late filing noticeOct 16, 2023Explanation requestSEC
424B3 · ProspectusOct 10, 2023Offer documentSEC
DEFA14A · Additional proxy materialOct 10, 2023Meeting noticeSEC
8-K · Current reportOct 10, 2023Current reportSEC
EFFECT · Notice that a registration is effectiveOct 6, 2023Other filingsSEC
POS AM · Amendment to an effective registrationOct 2, 2023Offer documentSEC
DEFA14A · Additional proxy materialSep 27, 2023Meeting noticeSEC
DEF 14A · Proxy statementSep 25, 2023Meeting noticeSEC
8-K · Current reportSep 25, 2023Current reportSEC
PRE 14A · Preliminary proxy statementSep 15, 2023Meeting noticeSEC
10-K · Annual reportSep 13, 2023Annual reportSEC
NT 10-K · Late filing noticeAug 30, 2023Explanation requestSEC
3 · Initial statement of ownershipAug 25, 2023Insider tradeSEC
8-K · Current reportAug 17, 2023FinancingSEC
424B3 · ProspectusJul 11, 2023Offer documentSEC
8-K · Current reportJul 11, 2023Management or board changeSEC
EFFECT · Notice that a registration is effectiveJul 11, 2023Other filingsSEC
CORRESP · Letter to the SECJul 6, 2023Other filingsSEC
UPLOAD · Letter from the SECJun 26, 2023Other filingsSEC
S-1 · Registration statementJun 21, 2023Offer documentSEC
8-K · Current reportMay 24, 2023Management or board changeSEC
10-Q · Quarterly reportApr 10, 2023Quarterly reportSEC
8-K · Current reportMar 8, 2023FinancingSEC
8-K · Current reportMar 2, 2023FinancingSEC
4 · Change in ownershipFeb 14, 2023Insider tradeSEC
EFFECT · Notice that a registration is effectiveFeb 10, 2023Other filingsSEC
EFFECT · Notice that a registration is effectiveFeb 10, 2023Other filingsSEC
EFFECT · Notice that a registration is effectiveFeb 10, 2023Other filingsSEC
EFFECT · Notice that a registration is effectiveFeb 10, 2023Other filingsSEC
EFFECT · Notice that a registration is effectiveFeb 10, 2023Other filingsSEC
EFFECT · Notice that a registration is effectiveFeb 10, 2023Other filingsSEC
EFFECT · Notice that a registration is effectiveFeb 10, 2023Other filingsSEC
EFFECT · Notice that a registration is effectiveFeb 10, 2023Other filingsSEC
POS AM · Amendment to an effective registrationFeb 3, 2023Offer documentSEC
POS AM · Amendment to an effective registrationFeb 3, 2023Offer documentSEC
POS AM · Amendment to an effective registrationFeb 3, 2023Offer documentSEC
POS AM · Amendment to an effective registrationFeb 3, 2023Offer documentSEC
POS AM · Amendment to an effective registrationFeb 3, 2023Offer documentSEC
POS AM · Amendment to an effective registrationFeb 3, 2023Offer documentSEC
POS AM · Amendment to an effective registrationFeb 3, 2023Offer documentSEC
POS AM · Amendment to an effective registrationFeb 3, 2023Offer documentSEC
8-K · Current reportFeb 1, 2023FinancingSEC
10-Q · Quarterly reportJan 9, 2023Quarterly reportSEC
8-K · Current reportDec 19, 2022Management or board changeSEC
8-K · Current reportDec 9, 2022Meeting outcomeSEC
DEFA14A · Additional proxy materialDec 7, 2022Meeting noticeSEC
8-K · Current reportDec 7, 2022Current reportSEC
DEFA14A · Additional proxy materialDec 6, 2022Meeting noticeSEC
8-K · Current reportDec 6, 2022Material contractSEC
4 · Change in ownershipNov 30, 2022Insider tradeSEC

This page holds 200 of 1,001 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from CytoDyn Inc.’s releases · as of Nov 12, 2026

Common shares
1,469,518,019
Fully diluted
1,469,518,019

Fully diluted

LineSharesAs of
Common shares1,469,518,019Nov 12, 2026

Share count over time

CountShares
Nov 22, 20261,469,518,019
Nov 12, 20261,394,350,333
May 31, 20261,373,517,000

Open Cap table

Shareholders

HolderSharesOf the companyValueAs of
Williams Jones Wealth Management, LLC.64,001<0.01%US$13,120Sep 30, 2026
Horizon Financial Services, LLC18,200<0.01%US$3,731Sep 30, 2026
Ancora Advisors LLC9,488<0.01%US$1,945Sep 30, 2026
Caz Investments LP4,000<0.01%US$820Sep 30, 2026
Benson Wealth Management INC198<0.01%US$41Sep 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Robert E. Hoffman
Other companies: Esperion Therapeutics, Inc. (Director · Since at least Apr 1, 2025); FibroBiologics, Inc. (Director · Since at least Jan 24, 2024); TuHURA Biosciences, Inc. (Director · Since at least Apr 11, 2018); Aravive Inc (Director · Oct 12, 2018 – Sep 12, 2019 · Past); Heron Therapeutics, Inc. (CFO & SVP, Finance · Apr 24, 2017 – Dec 19, 2019 · Past); Kura Oncology, Inc. (Director · May 12, 2016 – Jun 22, 2021 · Past); CombiMatrix Corp (Director · May 10, 2016 – Nov 14, 2017 · Past); MabVax Therapeutics Holdings Inc (Director · Aug 26, 2015 – May 19, 2017 · Past)
Chief Financial Officer · Since at least May 15, 2025
Alan Bruce Montgomery
Other companies: Xencor, Inc. (Director · Since at least Jun 23, 2016); Alder BioPharmaceuticals Inc (Director · May 26, 2016 – Oct 22, 2019 · Past)
Director · Jun 1, 2016 – Jul 12, 2018 · Past
Stephen M. Simes
Other companies: CervoMed Inc. (Chief Executive Officer, Director · Mar 5, 2014 – Jul 24, 2014 · Past); ANI Pharmaceuticals, Inc. (Vice Chairman, President & CEO, Director · Dec 14, 2007 – Jan 25, 2012 · Past)
Director · Since at least Oct 13, 2022
Alan P TimminsDirector · Jan 18, 2020 – Nov 24, 2021 · Past
Antonio MigliareseCFO · Mar 31, 2022 – Jan 3, 2024 · Past
Arian ColachisGC and Corporate Secretary · Mar 16, 2020 – Oct 23, 2020 · Past
Arvin Cyrus ArmanPresident · Jul 9, 2022 – Feb 13, 2023 · Past
Chris P RecknorSee Remarks · Mar 31, 2022 – Mar 31, 2022 · Past
Gordon A GardinerDirector · Jul 1, 2021 – Nov 24, 2021 · Past
Jacob LalezariChief Executive Officer · Since at least Nov 17, 2023
All 19 people
PersonSeat
Jordan G NaydenovDirector · Jul 1, 2009 – Oct 18, 2021 · Past
Karen J. BrunkeDirector · Since at least Mar 30, 2022
Lauren WilcoxenChief Operating Officer and Head of Regulatory Affairs · Since Nov 17, 2026
Lishomwa C. NdhlovuDirector · Since at least Nov 24, 2021
Michael A KlumpDirector · May 8, 2019 – Dec 19, 2019 · Past
Nader PourhassanPresident & CEO, Director · May 31, 2011 – Oct 18, 2021 · Past
Ryan DunlapDirector · Since at least Mar 20, 2026
Tanya Durkee UrbachDirector · Since at least Jan 3, 2024
Tyler BlokChief Legal Officer · Since at least Aug 15, 2023

Open People

Log in to ask 6ix AI your own questions about CytoDyn Inc.